Skip to content

9 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Mechanisms underlying the impact of testosterone on the phenotype of Brugada syndrome with SCN5A variant

Men are more likely to suffer from Brugada syndrome (BrS) than women. The aim of this study is to explore the underlying mechanisms by which testosterone affects the electrophysiology of BrS cardiomyocytes. Human induced pluripotent stem cell (hiPSC) lines generated from fibroblasts of a BrS patient harbor...

Y. Li, L. Chang, C. Yan et al. · 0 citations
Open access Oct 2026

Electrophysiological basis and pharmacological responses in short QT syndrome type 5: insights from iPSC-derived cardiomyocytes

Short QT syndrome type 5 (SQTS5) caused by CACNB2 variants is a rare inherited arrhythmia associated with a high risk of sudden cardiac death, yet its electrophysiological mechanisms and therapeutic options remain poorly defined. The study aimed to delineate the arrhythmogenic mechanisms of SQTS5 and evalu...

Z. Xue, F. Liu, Z. Meng et al. · 0 citations
Open access Oct 2026

NLRP3 inflammasome related signaling contributing to pathogenesis of Brugada Syndrome

Fever and inflammation can exacerbate the phenotype of Brugada syndrome (BrS). However, there is still a lack of experimental studies investigating the underlying mechanisms of fever or inflammation. NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome is activated during infections. This study a...

C. Yan, Z. Meng, R. Yan et al. · 0 citations
Open access Oct 2026

Influence of left ventricular ejection fraction on the clinical outcome of percutaneous coronary interventions in heart transplant patients.

BACKGROUND Although cardiac allograft vasculopathy (CAV) represents a common complication in heart transplantation (HTX) recipients, data investigating predictors of prognosis in patients with CAV are limited. The study sought to investigate the prognostic impact of left ventricular ejection fraction (LVEF) undergoing...

Luisa Elbinger, T. Schupp, M. Behnes et al. · 0 citations
Open access Aug 2026

Sex-Based Differences in Outcomes After Transcatheter Edge-to-Edge Repair for Severe Mitral Regurgitation.

Compared with men, women undergoing M-TEER presented at a more advanced age and with higher symptom burden than men, potentially reflecting sex-specific clinical trajectories and differing MR etiologies, but midterm outcomes, including all-cause mortality and HF rehospitalization, were comparable between sexes.

Reinhard Sauter, T. Schupp, M. Sauter et al. · 0 citations
Open access Aug 2026

Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.

Treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications, and these findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population.

Konstantinos D. Rizas, K. Mourouzis, D. Rath et al. · 3 citations
Open access Sep 2026

Impact of vascular and cardiac parameters on quality of life in patients undergoing catheter ablation for atrial fibrillation.

BACKGROUND Atrial fibrillation (AF) impairs quality of life (QoL), and catheter ablation (CA) has been shown to improve QoL in symptomatic individuals. The structural and functional cardiovascular determinants of impaired QoL remain incompletely understood. METHODS Participants with symptomatic AF scheduled for CA we...

M. Kruska, V. Liebe, Christian Fastner et al. · 0 citations
Aug 2026

Different diuretic regimes and long-term outcomes in heart failure with mildly reduced ejection fraction

Thiazide-only therapy was associated with the lowest mortality, while loop and combined diuretic therapy were linked to increased mortality and HF-rehospitalization, and Randomized trials investigating long-term diuretic therapy in HFmrEF patients are needed.

A. Schmitt, M. Behnes, M. Reinhardt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.